10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

ZEB1 antibody (Ascites)

Mouse Monoclonal Antibody (Mab)
Catalog # AM1878A

Specification

ZEB1 antibody (Ascites) - Product Information

Application	**WB, FC,E**
Primary Accession	P37275
Reactivity	**Human**
Host	**Mouse**
Clonality	**Monoclonal**
Isotype	**IgG1,K**
Calculated MW	**124074**
Antigen Region	**69-97**

ZEB1 antibody (Ascites) - Additional Information

Gene ID 6935

Other Names
Zinc finger E-box-binding homeobox 1, NIL-2-A zinc finger protein, Negative regulator of IL2, Transcription factor 8, TCF-8, ZEB1, AREB6, TCF8

Target/Specificity
This ZEB1 antibody is generated from mice immunized with a KLH conjugated synthetic peptide between 69-97 amino acids from human ZEB1.

Dilution
WB~~1:500~16000
FC~~1:10~50

Format
Mouse monoclonal antibody supplied in crude ascites with 0.09% (W/V) sodium azide.

Storage
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions
ZEB1 antibody (Ascites) is for research use only and not for use in diagnostic or therapeutic procedures.

ZEB1 antibody (Ascites) - Protein Information

Name ZEB1 (HGNC:11642)

Function Acts as a transcriptional repressor. Inhibits interleukin-2 (IL-2) gene expression. Enhances or represses the promoter activity of the ATP1A1 gene depending on the quantity of

cDNA and on the cell type. Represses E-cadherin promoter and induces an epithelial-mesenchymal transition (EMT) by recruiting SMARCA4/BRG1. Represses BCL6 transcription in the presence of the corepressor CTBP1. Positively regulates neuronal differentiation. Represses RCOR1 transcription activation during neurogenesis. Represses transcription by binding to the E box (5'-CANNTG-3'). In the absence of TGFB1, acts as a repressor of COL1A2 transcription via binding to the E-box in the upstream enhancer region (By similarity).

Cellular Location
Nucleus

Tissue Location
Colocalizes with SMARCA4/BRG1 in E-cadherin- negative cells from established lines, and stroma of normal colon as well as in de-differentiated epithelial cells at the invasion front of colorectal carcinomas (at protein level). Expressed in heart and skeletal muscle, but not in liver, spleen, or pancreas

ZEB1 antibody (Ascites) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

ZEB1 antibody (Ascites) - Images



ZEB1 Antibody (Ascites) (Cat. #AM1878a) western blot analysis in A549 cell line lysates (35µg/lane).This demonstrates the ZEB1 antibody detected the ZEB1 protein (arrow).

10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999



ZEB1 Antibody (Ascites) (Cat. #AM1878a) flow cytometric analysis of A549 cells (right histogram) compared to a negative control cell (left histogram).FITC-conjugated goat-anti-mouse secondary antibodies were used for the analysis.

ZEB1 antibody (Ascites) - Background

This gene encodes a zinc finger transcription factor. The encoded protein likely plays a role in transcriptional repression of interleukin 2. Mutations in this gene have been associated with posterior polymorphous corneal dystrophy-3 and late-onset Fuchs endothelial corneal dystrophy. Alternatively spliced transcript variants encoding different isoforms have been described.

ZEB1 antibody (Ascites) - References

Drake, J.M., et al. J. Biol. Chem. 285(44):33940-33948(2010) Takeyama, Y., et al. Cancer Lett. 296(2):216-224(2010) Nakahata, S., et al. Oncogene 29(29):4157-4169(2010) Mehta, J.S., et al. Invest. Ophthalmol. Vis. Sci. 49(1):184-188(2008) Manavella, P.A., et al. Biochem. Biophys. Res. Commun. 360(3):621-626(2007)

ZEB1 antibody (Ascites) - Citations

- Eupalinolide A induces autophagy via the ROS/ERK signaling pathway in hepatocellular carcinoma cells
- Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway.